C-CYTRRelation Therapeutics
single-cell multi-omics, functional assays, machine learning
discoverydiscovering
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CYTR
C-CYTRC-CYTRsingle-cell multi-omics, functional assays, machine learning
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Diseases of the skin associated with chronic immune driven conditions, including scleroderma, lupus, dermatomyositis, psoriasis, and atopic dermatitis, significantly impact skin integrity, function, and overall quality of life. These conditions can lead to severe disfigurement, discomfort, and systemic complications, necessitating long-term medical intervention. The prevalence of these skin disorders is rising globally, driven by genetic, environmental, and immunological factors. Unravelling the mechanisms leading to skin manifestations may shed further insights in the overall mechanisms of disease. The DERMATOMICS study will focus on understanding systemic sclerosis (SSc) biology. Systemic Sclerosis (SSc) is a highly heterogeneous rare autoimmune fibrotic condition affecting the skin and internal organs. SSc is classified as a Connective Tissue Disease (CTD), a family of conditions including Systemic Lupus Erythematosus, Sjogren Syndrome and Inflammatory Myositis, all characterised by an autoimmune process affecting the connective tissue of most organs, communed by the presence of anti-nuclear antibodies (ANA). In SSc, patients are affected by a combination of tissue and vascular fibrosis, on the background of a chronic inflammatory process, leading to the highest per patient morbidity and mortality across CTDs. The main driver of mortality to date is interstitial lung disease (ILD), which is the consequence of the fibrotic involvement of the lungs, leading to a progressive loss of functional lung volumes, and ultimately, derangement of lung circulation, hypoxia, increased risk of hospitalisation for lower respiratory infections and death. Current treatments for CTDs include general immunosuppressive treatments, not necessarily targeted to the specific mechanisms underlying their presentation, focusing on reducing inflammation and managing symptoms rather than addressing the underlying causes. Many of these therapies have limited effectiveness or are burdened with significant side effects. Therefore, there is a critical need to develop a comprehensive understanding of the cellular and molecular mechanisms underlying these disorders to identify novel therapeutic targets. Several factors contribute to the risk and severity of SSc, including genetic predisposition, environmental triggers, immune system dysregulation, and lifestyle factors such as diet and smoking. The interactions between these factors are complex and not fully understood. By recruiting participants with SSc, we aim to obtain skin punch biopsies for detailed molecular and genetic analysis. To increase the informative value of our study we plan to implement an extreme phenotype approach and include participants with opposite degrees of severity. Our study aims to elucidate the relationships between the molecular biology of skin cells, skin structure, genetic factors ("DNA"), and environmental influences. The goal is to identify and validate novel therapeutic targets that can lead to more effective and personalised treatment options for SSc, and more broadly for CTDs and CTD-associated skin and lung disease. Modern single-cell technologies will be employed to dissect the cellular diversity within the skin. These advanced techniques have revolutionised our understanding of many tissues, but skin tissues remain underexplored, especially in the context of chronic skin diseases. Protocols for skin punch biopsy and single-cell profiling are well-established, allowing us to systematically analyse how genetic variations influence skin structure and function.
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity. Current non-surgical approaches are limited to pharmaceutical agents that are not disease modifying and have poor patient tolerability due to side effect profiles. Developing a fundamental understanding of cellular bone homeostasis, including how key cell types affect tissue health, and offering novel therapeutic targets for prevention of bone disease is therefore essential. This is the focus of OSTEOMICS. A number of factors have been linked to increased risk of bone disease, including genetic predisposition, diet, smoking, ageing, autoimmune disorders and endocrine disorders. In our study, we will recruit patients undergoing elective and non-elective orthopaedic surgery and obtain surgical bone waste for analysis. This will capture a cohort of patients with bone disorders like OP and OA, in addition to patients without overt clinical bone disease. We will study the relationship between the molecular biology of bone cells, bone structure, genetics (DNA) and environmental factors with the aim of identifying and validating novel therapeutic targets. We will leverage modern single cell technologies to understand the diversity of cell types found in bone. These technologies have now led to the characterisation of virtually every tissue in the body, however bone and bone-adjacent tissues are massively underrepresented due to the anatomical location and underlying technical challenges. Early protocols to demineralise bone and perform single cell profiling have now been developed. We will systematically scale up these efforts to observe how genetic variation at the population level leads to alterations in bone structure and quality. Over the next 10 years, we will generate data to comprehensively characterise bone across health and disease, use machine learning to drive analysis, and experimentally validate hypotheses - which will ultimately contribute to developing the next generation of therapeutic agents.
How to: Update Item Distribution from Hierarchy Relation Skip To Main Content Account Settings Logout placeholder Account Settings Logout Filter: All Files Submit Search You are here:   How to: Update Item Distribution from Hierarchy Relation Item Distribution is a concept in Replenishment to define which Items are replenished to which Stores. This information is stored in the Item Distribution table which can be maintained on the Retail Item Card , the Distribution FastTab. Hierarchy Relations can be used to maintain this information in a simpler and faster way. Hierarchy Relations also
Authorities revise Memorandum of Understanding in relation to payments in the UK | FCA Skip to main content Skip to search box Search Search Main menu Main navigation About us Contact us Get in touch by phone, via our online form, or by post: Financial Conduct Authority 12 Endeavour Square London E20 1JN Contact us What we do About the FCA Enhancing market integrity Promoting competition Protecting consumers How we regulate Authorisation Enforcement Handbook of rules and guidance International standards and regulations Supervision How we operate Complain about us, the PRA or the … ancelling an authorisation or registration Check if a firm is authorised How to apply for authorisation or registration Regulated firms All firms Claims management companies Consumer credit firms Electronic money and payment institutions Funeral plan providers and intermediaries Innovation Hub Mutual societies Close menu Tasks for firms Approved persons Change in control Fees and levies Keeping your firm's information up to date Principals and appointed representatives F … l? Yes No What can we do to improve pages like this? What did you find helpful? Submit Feedback Leave this field blank Print Page Linkedin Twitter Share page On this page Outcome of the review Revision of the MoU The PSR More information Roles and responsibilities in payments regulation Accessibility Complain about us Copyright notice Corporate responsibility Cymraeg Freedom of information Modern Slavery and Human Trafficking Statement Privacy Sitemap Translated languages Soc
Avalon Project - Amendments Proposed by the Peace Conference, February 8-27, 1861 --> Avalon Home Document Collections Ancient 4000bce - 399 Medieval 400 - 1399 15 th Century 1400 - 1499 16 th Century 1500 - 1599 17 th Century 1600 - 1699 18 th Century 1700 - 1799 19 th Century 1800 - 1899 20 th Century 1900 - 1999 21 st Century 2000 - Amendments Proposed by the Peace Conference, February 8-27, 1861 ARTICLE XIII. SECTION I. In all the present territory of the United States north of the parallel of 36� 30' of north latitude, involuntary servitude, except in punishment of crime, is prohibited, I
Place of Supply in a Province – Personal Services, Services in Relation to Property and Telecommunication Services - Canada.ca Skip to main content Skip to "About government" Language selection Français fr / Gouvernement du Canada Search Search CRA Search Menu Main Menu Jobs and the workplace Immigration and citizenship Travel and tourism Business and industry Benefits Health Taxes Environment and natural resources National security and defence Culture, history and sport Policing, justice and emergencies Transport and infrastructure Canada and the world Money and finances Scienc … ubsection 165(2) at the provincial rate for that province, which results in the application of the HST at the relevant harmonized rate. 2. In the case of a taxable supply that is made in Canada, it is necessary to determine the province where the supply is made in order to apply the applicable tax and rate. Provincial place of supply rules exist for GST/HST purposes to determine the province in which a supply is deemed to be made. 3. Generally, the place of supply rules descr … (the regular GST/HST regime). 7. The rules explained in this memorandum do not apply to supplies of digital property or services made or facilitated by persons registered under the digital economy provisions of Subdivision E of Division II of Part IX of the ETA (simplified GST/HST registration). Subdivision E contains separate registration and place of supply rules for distribution platform operators and non-resident suppliers of digital property and services. For additional … for supplies of services are subject to specific place of supply rules that may apply to certain supplies of services. 10. The specific place of supply rules for services are found in Schedule IX and the Regulations, as follows: Along with the general place of supply rules for services, Division 3 of Part 1 of the Regulations sets out specific place of supply rules for services in relation to real property, most services in relation to tangible personal property, and personal … , section 12 of the Regulations provides that the rules under Division 3 do not apply if one of sections 4 to 5 of Part VI, or Part VII or VIII of Schedule IX instead apply to determine the place of supply. As explained in GST/HST Memorandum 3-3-7 , sections 4 to 5 of Part VI of Schedule IX set out the place of supply rules for particular transpo
Larissa C. Bergin | Lawyers | Jones Day Skip to content Search     LANGUAGES Deutsch español français português 中文(简体) 中文(繁體) 日本語     SEARCH   Lawyers Practices Insights Locations Values Firm News Inclusion Pro Bono Careers PRINT LANGUAGES Deutsch español français português 中文(简体) 中文(繁體) 日本語 Larissa C. Bergin Partner Washington + 1.202.879.5499 Connect:     Home Lawyers Larissa C. Bergin Share   Larissa Bergin's practice addresses emerging issues arising out of regulator enforcement of, and commentary on, the antitrust laws. Whether client antitrust concerns ari … neered safety-critical train connection systems and services for passenger rail rolling stock. HanesBrands and Gildan agree to combine to create a global basic apparel leader Jones Day advised Hanesbrands Inc. in the $2.2 billion acquisition of Hanesbrands by Gildan Activewear Inc. Verint agrees to be acquired by Thoma Bravo for $2 billion Jones Day advised Verint Systems Inc. (NASDAQ: VRNT), a global leader in Customer Experience (CX) Automation software, in connection with … sed BBA Aviation plc ("BBA") in the sale of its Ontic business to an investment fund affiliated with CVC Capital Partners for $1.365 billion. NASDAQ Technology AB acquires Cinnober Financial Technology AB Jones Day provided antitrust advice in relation to NASDAQ Technology AB's acquisition of Cinnober Financial Technology AB. Fairmount Santrol and Unimin merge creating Covia Jones Day advised Fairmount Santrol in its merger with Unimin Corporation, a wholly owned subsidiary o … s In on Orange Book Listing of Drug-Device Patents February 2024 Commentary OCC Proposal and Policy Statement on Bank Mergers Could Freeze the Banking Industry in Place View All   Additional Speaking Engagements August 7, 2024 Panel Discussion on the FTC’s Rule Banning Noncompete Agreements June 5, 2024 American Law Institute Continuing Legal Education - FTC Final Rule Noncompete Agreements: What It Means for Your Clients December 2023 NY Bar, 2023 Trade Secrets Symposium
Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life Med Care . 2001 Oct;39(10):1039-47. doi: 10.1097/00005650-200110000-00002. Authors G R Norman 1 , F G Sridhar , G H Guyatt , S D Walter Affiliation 1 Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. [email protected] PMID: 11567167 DOI: 10.1097/00005650-200110000-00002 Abstract Backgro
%PDF-1.6 %���� 1571 0 obj >stream h��[[s7��+|L�T\f�R��my�����q�*=��X�"^�(���� `�!)ʱ�6[�R5�Kh� ��~T��5�ȴ��]�议qgGu�Z��t���պu�ӣ�z�;32:4�5-n[3��k�t��^,�k�zzۭ��~q;����dq5�_���Q���O�i~~>}��[v�I��������O6�NM���\M��������M]M��j�R���/�� OP`�v���U��-;z��^̻�j� O& !v��_�����x�V��j:���ջ73�}�&��r1;?KwϿ=ͷ�tk�ۺ�������r[?�L������g'���r�7�����t�� tsL���0��f&�������=Q Иu� ����z:ψ�$�^v�St�]%�r�]��� � � D� |~�u��>%��Ľ�p���Іɵ�[���l ��� c�=A�7��{�2�\��u"�{"x��q"�r�g��ɩz�P:�ʧR���|�k�I�3)sV�9�eN�7�t�J���⯊�b�\�v3[O�f����7R��T}ST}���$ _�,�D_ݒD��J��&����X� �&� Ϋ����X �Ac����h[gi|RT4�8�:��C … p~��5F� ����˽�A�>��zÖ�#ö ��k,��B�Xe��r3�� endstream endobj 374 0 obj >stream application/pdf 2025-12-07T18:29:06Z LaTeX with hyperref 2025-12-10T11:46:49-05:00 2025-12-10T11:46:49-05:00 pdfTeX-1.40.26 False This is pdfTeX, Version 3.141592653-2.6-1.40.26 (TeX Live 2024) kpathsea version 6.4.0 uuid:3fc188eb-acb5-4230-8600-1470c9961d8d uuid:44d04b64-ee5d-4096-bcb5-31a81a844a9f endstream endobj 1417 0 obj >1 >62 >63 >]>>/PageMode/UseOutlines/Pages 1394 0 R/Type/Catalog>> endo
Insurance Investment Banking | Piper Sandler Main navigation What We Do What We Do Investment Banking Public Finance Research Fixed Income Alternative Asset Management Equities Sectors Sectors Chemicals Consumer Education Energy, Power & Infrastructure Financial Services Financial Sponsors Government Healthcare Real Estate Services & Industrials Technology About About Who We Are Our Commitments Our People News & Insights Conferences & Events Careers Investor Relations Transactions Transactions Investment Banking Public Finance Contact Search Invalid search inquiry Log In Log In
Partnering with GSK | GSK Skip to content Skip to search Behind the Science magazine Company Company Purpose, strategy and culture GSK at a glance History and heritage Board of Directors and Executive Committee Board information Governance Governance Committees Shareholders Sarbanes-Oxley Act 2002 Compliance Policy positions Codes, standards and reports Innovation Innovation Our leading scientists Our leading scientists Dr Tony Wood Dr Sabine Luik Dr Hesham Ahmed Abdullah Dr Kaivan Khavandi Dr Christopher Austin Research and development approach Pipeline Therapeutic areas Therapeutic areas Res … opment and Supply (MDS) Genomic sciences Technology Early careers Early careers Application process Apprentice programmes Internships and placements Graduate programme Graduate programme Business operations Engineering Manufacturing & supply Commercial Research & development Digital & tech Manufacturing sciences & technology Post graduate opportunities Frequently asked questions Veterans Our global and regional hubs How we hire How we hire Fraudulent internet … and bring life-saving treatments to patients more efficiently. Partner with us Submit ideas or contact us for collaboration opportunities: Academics, Biotechs and TechBios Medicines Vaccines Supported studies Some of our recent collaborations By working with partners, we can achieve more and ensure faster innovation to address disease areas of high unmet need for as many people as possible. Our collaborations with our partners underscore our commitment to finding novel treat
EX-10.30 4 dex1030.htm COLLABORATION AND LICENSE AGREEMENT Collaboration and License Agreement Exhibit 10.30 Execution Version Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN AVEO PHARMACEUTICALS, INC., AVEO PHARMA LIMITED AND ASTELLAS PHARMA INC. ASTELLAS US LLC ASTELLAS PHARMA EUROPE LIMITED EFFECTIVE AS OF FEBRUARY 16, 2011 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS … with ASTELLAS in the Joint Development and Commercialization Territory, and to grant to ASTELLAS such exclusive rights with respect to the Royalty-Bearing Territory, all as more particularly set forth below. N OW , T HEREFORE , in consideration of the foregoing premises and the covenants and obligations set forth in this Agreement, the Parties agree as follows: ARTICLE 1 DEFINITIONS The initially capitalized terms below in this Article have the following meanings as used thr … RBT Commercialization Plan ”. ASTELLAS RBT Commercialization Plan means a rolling three (3) year plan that describes API’s Commercialization plans for Licensed Compounds, Licensed Products and Licensed Product Biomarkers in the Field in the Royalty-Bearing Territory for such period, including subject matter as called for in Section 6.3(a)(i). The ASTELLAS RBT Commercialization Plan may be updated or amended pursuant to Section 6.3(a)(ii). 2 1. … 47; ASTELLAS RBT Development Plan ”. ASTELLAS RBT Development Plan means a rolling three (3) year plan that describes API’s Development plans for Licensed Compounds, Licensed Products and Licensed Product Biomarkers in the Field in the Royalty-Bearing Territory for such period, including specific studies to be performed (including post-marketing studies), anticipated timelines thereof, and other subject matter as called for in Section 3.2(b)(i). The ASTELL … loped by or on behalf of the receiving Party or its Affiliates without the aid, application or use of the disclosing Party’s Confidential Information (the competent written proof of which must be contemporaneous with such independent development). 1.23 “ Control ”. Control means, with respect to any Know-How, Patent or other intell
New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities http://www.legislation.gov.uk/id/ukpga/1968/16/crossheading/powers-exercisable-in-relation-to-land-acquired-by-development-corporations-or-highway-authorities Powers exercisable in relation to land acquired by development corporations or highway authorities start=1968-03-28; New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities currently in force http://www.legislat … ed by development corporations or highway authorities 2026-06-01T17:32:31+01:00 application/xml XML RDF/XML version of New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities currently in force http://www.legislation.gov.uk/ukpga/1968/16/crossheading/powers-exercisable-in-relation-to-land-acquired-by-development-corporations-or-highway-authorities/data.rdf Powers exercisable in relation to … ed by development corporations or highway authorities 2026-06-01T17:32:31+01:00 application/rdf+xml RDF/XML AKN version of New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities currently in force http://www.legislation.gov.uk/ukpga/1968/16/crossheading/powers-exercisable-in-relation-to-land-acquired-by-development-corporations-or-highway-authorities/data.akn Powers exercisable in relation … ed by development corporations or highway authorities 2026-06-01T17:32:31+01:00 application/akn+xml AKN HTML snippet version of New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities currently in force http://www.legislation.gov.uk/ukpga/1968/16/crossheading/powers-exercisable-in-relation-to-land-acquired-by-development-corporations-or-highway-authorities/data.xht Powers exercisable in rel … ed by development corporations or highway authorities 2026-06-01T17:32:31+01:00 application/xhtml+xml HTML snippet HTML5 version of New Towns (Scotland) Act 1968 Crossheading; Powers exercisable in relation to land acquired by development corporations or highway authorities currently in force http://www.legislation.gov.uk/ukpga/1968/16/crossheadi
Relation announces two strategic collaborations with GSK to --> Accessibility: Skip TopNav Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis December 10, 2024 02:00 ET | Source: Relation Therapeutics Relation Therapeutics Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collabor … suring targets are robustly validated before entering the clinic. Relation will apply its platform to a number of related fibrotic conditions and also osteoarthritis. GSK will have worldwide development and commercialisation rights to any resulting targets. “Working with Relation enables us to gain deep and precise insights into human causal biology and apply these to therapeutic discovery through a data-driven approach, supported by Relation’s proprietary platform,” said Kai
Adaptimmune Quarterly report [Sections 13 or 15(d)] Quarterly report [Sections 13 or 15(d)] Cover Document and Entity Information Financial Statements CONDENSED CONSOLIDATED BALANCE SHEETS CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/LOSS (Parenthetical) CONDENSED CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Notes to Financial Statements General Summary of Significant Acco
Relation Buys True-Course Aviation Insurance Services VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Relation Buys True-Course Aviation Insurance Services By Amit Chowdhry • Apr 15, 2025 Relation Buys True-Course Aviation Insurance Services Relation Insurance Services announced it has acquired the assets of True-Course Aviation Insurance Services. The deal went into effect on March 31, 2025. The terms of the deal were undisclosed. Based in Camarillo, California, True-Course Aviation Insurance has expertise in aviation risk solutions. And Alejandro Galioto (
H Group Benefits acquired by insurance broker Relation - Reinsurance News Home News # By combining our experience in knowledge management and reinsurance insight with technology, we aim to bring you the reinsurance industry news that matters online and in our daily emails. Use these categories to find news that interests you, or to view all of our news in chronological order just select “Read all news”. Read all news It’s free to sign up and get all of our reinsurance news by email every day. Get our Reinsurance News emails # Monte Carlo Rendez-Vous Reinsurance Renewals Re/Insurer results Peop
Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome Defective B-lymphocyte function in homosexual men in relation to the acquired immunodeficiency syndrome Ann Intern Med . 1984 Dec;101(6):757-63. doi: 10.7326/0003-4819-101-6-757. Authors S G Pahwa , M T Quilop , M Lange , R N Pahwa , M H Grieco PMID: 6388451 DOI: 10.7326/0003-4819-101-6-757 Abstract Patients with the acquired immunodeficiency syndrome manifest a wide spectrum of immunologic abnormalities. Polyclonal and antigen-specific differentiation of B lymphocyte
Human Capital in Corporate Venture Capital Units and Its Relation to Parent Firms’ Innovative Performance - University of Twente Research Information Skip to main navigation Skip to search Skip to main content University of Twente Research Information Home Search content at University of Twente Research Information Home Profiles Research units Projects Research output Datasets Activities Prizes Press/Media Human Capital in Corporate Venture Capital Units and Its Relation to Parent Firms’ Innovative Performance David Bendig , Vincent Göttel * , David Eckardt , Colin Schulz * Corresponding autho … similar technologies. For all open access content, the relevant licensing terms apply We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies University of Twente Research Information data protection policy Link opens in a new tab About web accessibility Link opens in a new tab Report vulnerability Link opens in a new tab Contact us
Relation Insurance Acquired by BayPine in Major Brokerage Shake-up - BriefGlance.com Skip to main content BriefGlance.com INTELLIGENCE Intelligence Market pulse Wire Media Center Contact Sign In Menu × Intelligence Market pulse Wire Media Center Contact Sign In Home Pamela Cox Relation Insurance Acquired by BayPine in Major Brokerage Shake-up Relation Insurance Acquired by BayPine in Major Brokerage Shake-up 📊 Key Data 100+ acquisitions under Aquiline's ownership since 2019 230,000 clients served by Relation Insurance $315 million in brokerage revenues (2024) 🎯 Expert Consensus Exp
Relation Partners with Deerfield Management on Lab-in-the-Loop Collaboration | Relation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
atra-ex1037_103.htm Exhibit 10.37 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. EXECUTION VERSION FOURTH AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH AND ATARA BIOTHERAPEUTICS, INC. Table of Contents Page 1. DEFINITIONS 2 2. SCOPE OF THE COLLABORATION 9 3. GOVERNAN … shall have the meaning given in Section 2.3(a) . 1.68 “ New Research Proposal ” shall have the meaning given in Section 2.3(b) . 1.69 “ NHL ” shall have the meaning given in Section 2.1(a) . 1.70 “[***]” shall have the meaning given in Section 2.1(a) . -6- 1.71 “ Option ” shall have the meaning given in the License Agreement. 1.72 “ Original Research Agreement ” shall have the meaning given in … lusion within the Research Collaboration, Institute shall prepare and present a proposal (a “ New Research Proposal ”) to the JSC for discussion. Any New Research Proposal shall include, at a minimum: (i) the Target(s) for such New CTL Products or Program [***], as applicable, (ii) a description of the proposed research and development activities, including an estimated timeline for such development, (iii) a good faith estimated budget for such developm … 20; New Research Information Package ”). Any such New Research Proposal shall be presented to the JSC no less than thirty (30) days prior to the JSC meeting at which such New Research Proposal is to be considered. (c) The JSC shall discuss any New Research Proposal at the next JSC meeting following the delivery by Institute of the New Research Information Package, and shall determine whether the Parties should include the New Research Program within the scope … such amendments, all other terms and conditions of the License Agreement shall apply equally to any New CTL Product and the Program [***] as to any other Licensed Product, provided that (i) the Milestone Payments applicable to any such New CTL Product shall be those set forth in the column under the heading “Research Milestone Payments 
Human capital in corporate venture capital units and its relation to parent firms' innovative performance --> --> --> Advanced search Economic literature: papers , articles , software , chapters , books . Authors Institutions Rankings Help/FAQ MyIDEAS More options at page bottom Economic literature Authors Institutions Rankings Help/FAQ MyIDEAS (now improved) --> Advanced search Browse Econ Literature Working papers Journals Software components Books Book chapters JEL classification More features Subscribe to new research RePEc Biblio Author registration Economics Virtual Seminar Calendar Conf … f Economic Research, Inc. Dushnitsky, Gary & Yu, Lei, 2022. " Why do incumbents fund startups? A study of the antecedents of corporate venture capital in China ," Research Policy , Elsevier, vol. 51(3). Mastrogiorgio, Mariano & Gilsing, Victor, 2016. " Innovation through exaptation and its determinants: The role of technological complexity, analogy making & patent scope ," Research Policy , Elsevier, vol. 45(7), pages 1419-1435. Tom Elfring, 2005. " Dispersed and Focused Corp … effrey M, 1996. " Econometric Methods for Fractional Response Variables with an Application to 401(K) Plan Participation Rates ," Journal of Applied Econometrics , John Wiley & Sons, Ltd., vol. 11(6), pages 619-632, Nov.-Dec.. Leslie E. Papke & Jeffrey M. Wooldridge, 1993. " Econometric Methods for Fractional Response Variables with an Application to 401(k) Plan Participation Rates ," NBER Technical Working Papers 0147, National Bureau of Economic Research, Inc. Yang, Yi & Na … e , Elsevier, vol. 81(C). Dushnitsky, Gary & Yu, Lei, 2022. " Why do incumbents fund startups? A study of the antecedents of corporate venture capital in China ," Research Policy , Elsevier, vol. 51(3). Varkey K. Titus Jr. & Brian S. Anderson, 2018. " Firm Structure and Environment as Contingencies to the Corporate Venture Capital-Parent Firm Value Relationship ," Entrepreneurship Theory and Practice , , vol. 42(3), pages 498-522, May. Patrick Röhm, 2018. " Exploring the land
The Dynamic Relation Between IS Integration and the Merger and Acquisition Process | Lund University School of Economics and Management (LUSEM) Skip to main content To Lund University Contact us All staff Student at LUSEM Library Alumni LUSEM Staff Pages Departments and divisions News & Events News articles Calendar LUSEM newsletter To Lund University Swedish website Listen Search Header search Header search Swedish website Listen Study Interested in studies? Application and admission Bachelor's programmes Master's programmes Courses International opportunities Career opportuniti
DCVC | Relation unveils atopic diseases agreement with Novartis—$55… Skip to content DCVC Close Menu Companies About DCVC Bio Team News & Insights Careers Media Resources Feature Read our 2024 Climate Impact Report FEATURE: Read our 2024 Climate Impact Report Dismiss DCVC Companies About DCVC Bio Team News & Insights Careers Search DCVC Search Search Open Menu News & Insights News Relation unveils atopic diseases agreement with Novartis — $ 55 million up front and up to $ 1 . 7 billion in milestone-based payments; DCVC, NVIDIA NVentures, and Magnetic Ventures co-lead $ 26 M fundrai … ograms have been proven in clinical trials. Later, industry partnerships help fund those clinical trials, which are too expensive for early-stage venture-capital and private-equity backers to bear alone. Additionally, a portion of the upfront and research payments can be put toward advancing the company’s technology platform, including its frontier AI models, atlases of biological data, and labs. Partners strongly support this use of their investments, because they s
Relation Insurance Services Acquires Rummel Associates VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Relation Insurance Services Acquires Rummel Associates By Amit Chowdhry • Mar 11, 2026 Relation Insurance Services Acquires Rummel Associates Relation Insurance Services announced that it has acquired the assets of Rummel Associates, expanding the brokerage firm’s presence in the Chicago area and adding additional expertise across commercial and personal insurance. The transaction became effective January 31, 2025. Financial terms of the deal were not discl
Mintz Advises Relation Therapeutics on Additional Funding Round, Including Strategic Investment from Novartis | Mintz Skip to main content Menu Why Mintz Meet Our Managing Member Our History Innovation Diversity Pro Bono Community Service Alumni Leadership Awards & Recognition International Law Firm Network In Memoriam Our People Our Services Insights Center Events News & Press Releases Alumni Careers Offices News Search Search Open Search Home All News Mintz Advises Relation Therapeutics on Additional Funding Round, Including Strategic Investment from Novartis Mintz Advises Relation T
Relation bolsters US foothold with First Insurance Switch language: .translate --> LI Menu Search Sections Home News Analysis Features Comment & Opinion Data Insights Sectors FinTech Payments Technology Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Releases White Papers Partner Content Events Buy Reports Premium Insights GlobalData About Us Advertise With Us Contact Us Our Marketing Solutions GlobalData Repo
Relation collaborates with Novartis on therapeutics for atopic diseases | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for ear … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Relation collaborates with Novartis on therapeutics for atopic diseases Member news 9 Decem
Relation Therapeutics Secures Funding for Drug Discovery | Vega Shah posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … ies B financing (IDG Capital, SongQing Capital, WuXi AppTec’s Corporate Venture Fund, Temasek) ➡️ Advancing its lead KRAS inhibitor elisrasib into Phase 3 studies. SanegeneBio Raised $110M in Series B funding (Sino Biopharm, Legend Capital, Vivo Capital) ➡️ Developing RNAi medicines. #biotech #lifescience 17 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Rachel Braun Scherl 6mo Report this post GSK has launched a $50 million venture capital fund … ovation #venturecapital #futureofhealth GSK launches 50 million venture capital fund to invest in pioneering bioelectronic medicines and technologies | GSK gsk.com 186 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in James Mawson 6mo Report this post Nice scoop by Kyle at endpoints on the spinout of GSK’s second corporate venture capital unit, Action Potential VC, to form Synapse. APVC launched in 2013 alongside GSK's internal Bioelectr … s News has learned. A new entity steered by former APVC leaders, called Synapse Fund, has received backing from SR One, Revelation Partners and other investors. GSK formed APVC with $50 million in 2013. The UK pharma giant is also involved in the bioelectronic field via Galvani, its up to $713 million joint venture with Alphabet's Verily Life Sciences. #gsk #corporateventurecapital #apvc #galvani #bioelectronics #neuromodulationstartups https://lnkd.in/gPbHR_P2 GSK spins out … cs #neuromodulationstartups https://lnkd.in/gPbHR_P2 GSK spins out corporate VC fund focused on bioelectronic tech endpoints.news 8 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kyle LaHucik 6mo Report this post GSK spun out its biotech-focused corporate venture unit SR One in 2020, and now it's separating its bioe
Relation Insurance acquires assets of Seattle-based insurer | Insurance Business CONTINUE TO SITE CONTINUE TO SITE My account Logout Login News Insurance News Industry News Columns Diversity & Inclusion Mergers & Acquisitions Legal Advisory Board Risk Management TV E&S Reinsurance Resources Annual Guides Business Strategy E-mag Events Guides IB Talk Industry Reports Insurance Companies Leaders Network Risk, Compliance & Legal Opinion Premium Content Webinars White papers Best In Insurance Specialty Benefits Cannabis Catastrophe & Flood Claims Construction & Engineering Cyber Environmental E&S
Appendix 1: Statutory requirements in relation to strategic planning and annual reporting - Alcohol and Drug Partnerships: delivery framework - gov.scot Skip to main content Accessibility help Information We use cookies to collect anonymous data to help us improve your site browsing experience. Click 'Accept all cookies' to agree to all cookies that collect anonymous data. To only allow the cookies that make the site work, click 'Use essential cookies only.' Visit 'Set cookie preferences' to control specific cookies. Accept all cookies Use essential cookies only Set cookie preferences Your coo … Planning Partners [11] Community Empowerment (Scotland) Act 2015 [Note: Duties apply to locally identified priorities. Only applies to alcohol or drugs where the CPP agrees that these or related issues are one of the priorities for the locality] Local Outcome Improvement Plan Community Planning Partners [12] Community Empowerment (Scotland) Act 2015 [Note: Duties apply to locally identified priorities. Only applies to alcohol or drugs where the CPP agrees that these or relat
Relation Therapeutics Team Portfolio What We Do Overview Investment Intelligence Philanthropy About About Deerfield News Affiliates Careers Contact Cure Cure What We Do Investment Portfolio Relation Therapeutics Therapeutics Therapeutics Current Initial Transaction Details Transaction Date March 2024 Purpose of Financing Venture Stage of Company Early Stage Structure of Financing Equity Relation is a biotechnology company discovering and developing transformational medicines, with experimental and computational systems at its core. The company’s Lab-in-the-Loop approach combines single cell mu
Relation Insurance Announces Acquisition of Independent Brokerage S.T. Good Insurance, Inc. - Relation Insurance Skip to content Insurance Employee Benefits Health & Wellness Programs Compliance & HR Support Custom Benefits Consulting Retirement Benefits Executive Benefits Pharmacy Benefits Voluntary Benefits Business Insurance Workers Compensation General Liability Commercial Property Commercial Auto Loss Control Claims Management & Advocacy Cyber Liability Surety & Bonds Executive Liability Professional Liability Captives & Alternative Risk Business Owners Policy Sma … binars Type Press Release News Article Blog Post Date Newest First Oldest First Apply Company News Relation Insurance Announces Acquisition of Independent Brokerage S.T. Good Insurance, Inc. WALNUT CREEK, Calif.– Relation Insurance Services (“Relation”), a privately owned insurance brokerage that offers property and casualty, risk management, employee benefits, and TPA-consulting services through its family of brands across the United States, announced today it has acqu
Investor Relations | Tata Communications <img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1705902170274878&amp;ev=PageView&amp;noscript=1"> Skip to content Sign in Experience & Buy Customer Portal Effortlessly buy, track and manage your services and platforms. Sign In New customer? Start here Experience Hub Explore our digital fabric through engaging demos, interactive calculators, and insightful surveys. Sign Up Existing user? Sign in Careers Investors Contact Us Digital Fabric Products All Products Network Future-ready solutions for better, … al Investor Meeting Update on dissolution of a wholly owned indirect subsidiary Grant of stock options under ‘Tata Communications Limited - Stock Unit Plan 2023’ Dissolution of a wholly owned indirect subsidiary Intimation regarding issuance, allotment and listing of Commercial Paper amounting to ₹300 crore Change in Senior Management Personnel Redemption of Commercial Paper amounting to ₹200 crore Appointment of Chief Financial Officer Outcome of Board Meeting scheduled on J … cured, Listed, Redeemable Non-Convertible Debentures on Private Placement basis Grant of stock options under ‘Tata Communications Limited - Stock Unit Plan 2023' Intimation of Credit Ratings under the SEBI (LODR) Regulations, 2015 Intimation of Schedule of Analyst / Institutional Investor Meetings Intimation of Schedule of Analyst / Institutional Investor Meetings – Update Redemption of Commercial Paper amounting to ₹250 crores Intimation regarding issuance, allotment and lis … tment of Mr. N. Ganapathy Subramaniam as the Chairman of the Board of Directors Grant of stock options under ‘Tata Communications Limited - Stock Unit Plan 2023’ Intimation of Schedule of Analyst / Institutional Investor Meetings Board Meeting intimation April 22, 2025 Change in name of the Company’s Registrar and Share Transfer Agent Board Meeting intimation January 22, 2025 Certificate with regards to Commercial Papers Grant of stock options under ‘Tata Communications Limit … eeds of NCDs Intimation regarding Centralised Database for corporate debentures Grant of stock options under ‘Tata Communications Limited - Stock Unit Plan 2023' Redemption of Commercial Paper amounting to ₹465 crore Appointment of Independent Director Institutional Investors & Analysts Day 2025 - Intimation of recording Institutional Investo
Mintz Advises Relation Therapeutics on Strategic Investment from GSK | Mintz Skip to main content Menu Why Mintz Meet Our Managing Member Our History Innovation Diversity Pro Bono Community Service Alumni Leadership Awards & Recognition International Law Firm Network In Memoriam Our People Our Services Insights Center Events News & Press Releases Alumni Careers Offices News Search Search Open Search Home All News Mintz Advises Relation Therapeutics on Strategic Investment from GSK Mintz Advises Relation Therapeutics on Strategic Investment from GSK Mintz advised Relation , an ind
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Annual Report | Leeds Safeguarding Children Partnership Skip to main content Concerned about a child Safeguarding Assessment Search Menu Type your search below Search Main menu The Partnership News Children and Young People Families Businesses Practitioners Training Concerned about a child Section 11 Audit Annual Report Sub menu Independent Scrutineer statement About Leeds Safeguarding Children Partnership LSCP Executive LSCP Subgroups Funding arrangements What do we know - Data LSCP Reviews 2023 - 2024 Learning themes Multi-agency training Priorities 2024 - 2025 Voice and influence of childre … g Together to Safeguard Children, in good time and ahead of the required deadline. This involved the revision and publication of our multi-agency safeguarding arrangements, including the designation of Lead Safeguarding Partners (LSPs), in line with the new guidance requiring this function to be held at Chief Executive and Chief Constable levels to reflect senior accountability for safeguarding arrangements. In addition, Education and Schools have become the fourth saf
News Headline | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News News Headline View all In the news Press releases Scientific publications Featured News Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases In the news 09 Dec 2025 Read More News Articles The Times | GSK puts its faith in London biotech firm with $300m deal Press release 10 Dec 2024 Read More A community effort to track commercial single-cell and spatial ’omic technologies and business trends Scientific publi
Results, reports and presentations | Standard Life plc We use strictly necessary cookies when you visit our website to give you the best experience possible and to keep things secure. We'd also like your consent to set other cookies to help us improve our website and to tailor the marketing you see. Manage Settings Decline All Accept All Skip navigation Javascript is disabled in your browser and some features on this website, like the main navigation or search may not work correctly Customer logins Our brands Standard Life Standard Life has been trusted to look after people’s life savings … agreed a total consideration of £2 billion to acquire 100% of Aegon UK. We will fund this through a combination of cash, debt and 181 million new shares in Standard Life issued directly to Aegon. As already mentioned, the consideration represents 83% of the acquired unrestricted Tier 1 capital, ensuring attractive returns for our investors. While the transaction is subject to customary regulatory approvals, it is not contingent on a shareholder vote. Neither our own nor Aegon … eted the deleveraging programme, that gets bigger and none of that is needed to fund the delivery of the synergies, just to be crystal clear. Perfect. That's very, very helpful, thank you. Thank you. Our next question comes from Abid at Panmure Liberum, if you'd like to go ahead and ask your question. Oh, Hi. Morning all. Can you hear me? Yes, loud and clear. Great. Okay, so I've got a few questions as well. The first one is on the return metrics. Just wondering what the deal … ReAssure Life Limited, Standard Life Assurance Limited, Standard Life Pensions Fund Limited, Sun Life Assurance Company of Canada (U.K.) Limited and PA(GI) Limited. This report is provided below. At present this waiver does not extend to Standard Life International Designated Activity Company and Phoenix Life Assurance Europe Designated Activity Company, the individual reports for these entities is provided below. 2025 2024 2023 2022 2021 2020 Archive 31 Dec 2025 Standard Li … t Us Media Contacts Investor Contacts Speak Up Learn more Careers Standard Life Fund Managers Glossary Learn more Careers Standard Life Fund Managers Glossary Useful links Privacy hub Human rights and modern slavery Financial crime prevention compliance Abbey Life Staff Pension Scheme Sitemap Useful links Privacy hub Human rights and modern slave
Microsoft 2025 Annual Report You are using an outdated browser. Please upgrade your browser to improve your experience and security. Microsoft Annual Report 2025 Home Home Shareholder Letter Financial Review Financial Review Business Business General Operating Segments Human Capital Resources Operations Research & Development Distribution, Sales & Marketing Licensing Options Government Regulation Available Information Discussion & Analysis Market Risk Income Statements Balance Sheets Cash Flows Statements Stockholders' Equity Notes Notes Accounting Policies Earnings Per Share Other … And we continue to invest in sovereign cloud offerings to meet the unique data residency needs of governments and industries worldwide. We have made meaningful progress on the next frontier in cloud systems: quantum. We announced Majorana-1 , the first quantum chip with a topological core, and deployed the world’s first operational Level 2 quantum computer in partnership with Atom Computing. In data and analytics, Microsoft Fabric is becoming the unified platform for the AI … es; datacenters that coordinate and aggregate diverse customer, geographic, and application demand patterns, improving the utilization of computing, storage, and network resources; and multi-tenancy locations that lower application maintenance labor costs. We prioritize security above all else and we offer our customers integrated AI-driven products addressing security, compliance, identity, management, and privacy across customers’ multi-cloud, application, and device assets … (“CRM”), and supply chain management, as well as agentic AI and other low code application development platforms, for small and medium businesses, large organizations, and divisions of global enterprises. Dynamics revenue is driven by the number of users licensed and applications consumed, expansion of average revenue per user, and the continued shift to Dynamics 365, a unified set of cloud-based intelligent business applications, including our low code development platforms … d Power Automate. Competition Competitors to Office include software and global application vendors, web-based and mobile application companies, AI-first application companies, as well as local application developers. We compete by providing secure, integrated industry-specific, and easy-to-use productivity and collaboration tools and services th
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
How Collaborations Are Helping London Biotechs Find A… | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News News How Collaborations Are Helping London Biotechs Find A Route To Market In the news August 12, 2025 “ The importance of collaboration for startups https://www.forbes.com/sites/trevorclawson/2025/08/12/how-collaborations-are-helping-london-biotechs-find-a-route-to-market/ Partnerships and collaborations provide an important means for life sciences and healthtech startups to validate their technologies, secure
Rosie Rodriguez | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Team Rosie Rodriguez President, Growth Rosie Rodriguez is Relation’s President of Growth. Rosie brings over 18 years of successful Research and Development experience in Pharmaceuticals and Life Sciences. She is a senior executive accomplished in Clinical Development, Alliance and Portfolio Management and Business Strategy. Rosie holds a PhD from The Institute of Cancer Research (CRUK). LinkedIn Relation Therapeutics Contact [email protected] Hea
Raj Dattani | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Team Raj Dattani Head of Clinical Development & Portfolio Strategy As Head of Clinical Development & Portfolio Strategy, Raj leads asset development and portfolio strategy at Relation, bridging scientific innovation with clinical translation. He holds a BSc from London and completed graduate-entry Medicine at the University of Oxford as a Crankstart Scholar. Prior to joining Relation, Raj worked across clinical development, strategic advisory and
Relation Therapeutics Jobs and Careers | Welcome to the Jungle (formerly Otta) Jobs Explore jobs Companies Discover companies Sign in Sign in Relation Therapeutics Drug discovery & development 21-100 employees Healthcare B2B Machine Learning MedTech London, UK HQ Jump to section Company mission Our take Funding Leadership and people Office Company mission To deploy cutting edge technology for the good of patients. Our take Despite advancements in medicine, many diseases are as yet untreatable by modern pharmaceuticals. Relation Therapeutics is leveraging the power of machine learning to po
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
United States - Mintz Advises Relation Therapeutics on Additional Funding Round, Including Strategic Investment from Novartis European Union Home About Mondaq Topics Back Topics Accounting and Audit Antitrust/Competition Law Cannabis & Hemp Compliance Consumer Protection Coronavirus (COVID-19) Corporate/Commercial Law Criminal Law Employment and HR Energy and Natural Resources Environment Family and Matrimonial Finance and Banking Food, Drugs, Healthcare, Life Sciences Government, Public Sector Immigration Insolvency/Bankruptcy/Re-Structuring Insurance Intellectual Property International L
Senior/Principal Data Scientist - Computational Genomics @ Relation Therapeutics | DCVC Job Board DCVC Close Menu Companies About Team News & Insights Reports Careers Media Resources DCVC Companies About DCVC BIO team News & Insights Careers Open Menu Careers Our companies are made up of insanely talented people driven to change the world — and many of them are hiring. If you have drive, expertise, and a taste for adventure, we wholeheartedly encourage your interest. 0 Companies Hiring 0 Open Roles Search jobs Explore companies Join talent network Talent My job alerts Senior/Principa
Relation Therapeutics | Khosla Ventures Job Board Menu Close About Portfolio Team Current Learn [email protected] [email protected] 2128 Sand Hill Road Menlo Park, CA 94025 (650) 376.8500 People Matter Join the teams that make the Impossible Happen. Search jobs Explore companies Join talent network Talent My job alerts Relation Therapeutics relationrx.com Locations England, UK · London, UK · Mile End, London, UK · Kingston Vale, London SW15, UK industry Biotechnology · Biotechnology Research · Genetics · Health Care · Medical Size 51 - 200 employees Stage Other founded in 2019 Socia
Transcribed: Biotech Journeys & Breakthrough Lessons | Benchling Interview Series Skip to Main Content Transcribed Personal journeys and hard-earned lessons behind biotech’s biggest breakthroughs Featured interview with Lindsay Edwards Chief Technology Officer Relation CTO of Relation Therapeutics Lindsay Edwards on why virtual cells are overhyped, why legacy data is worth less than you think, and what it will actually take for machine learning to change drug discovery. View now Podcast available on More stories Watch Jacob Berlin on why chemistry is the last frontier for AI drug discovery
XML 43 R19.htm IDEA: XBRL DOCUMENT v3.25.4 Research, Collaboration and Licensing Agreements 12 Months Ended Dec. 31, 2025 License Agreements Research Collaborations And Development Agreements [Abstract]   Research, Collaboration and Licensing Agreements Research, Collaboration and Licensing Agreements Revenue recognized from the Company’s strategic partnerships is summarized as follows: Year ended December 31, 2025 2024 2023 Jazz: Milestone revenue $ —  $ 25,000  $ —  Development support payments 5,616 2,835  52,619  Drug supply for ongoing studi … ted through the use of the Company’s Azymetric platform. The Company will apply its Azymetric platform in combination with BMS’s proprietary targets to create novel bispecific antibodies for which BMS has an option to develop and commercialize a certain number of products (“Commercial License Option”). Upon the execution of the Agreement, the Company received an upfront payment of $8.0 million. This agreement was expanded in 2018 to increase the number … 7;s existing collaboration agreement with BMS was amended to expand the license grant to include the use of the Company’s EFECT platform for the development of therapeutic candidates and to extend the research term. The amendment included an upfront expansion fee of $12.0 million paid to the Company and all other financial terms were unchanged. The Company’s performance obligations in relation to the upfront fee were met on the date of amendment. Accordingly, … llectual property arising from the collaboration and after a period of time, to grant licenses to such intellectual property for development of additional products by third parties without any royalty or milestone payment to GSK. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance. No development or commercial milestone payments or royalties have been received
EX-10.15 2 dex1015.htm COLLABORATION AGREEMENT Collaboration Agreement Exhibit 10.15 COLLABORATION AGREEMENT T HIS C OLLABORATION A GREEMENT (the “Agreement” ) is entered into as of October 26, 2009 (the “Effective Date” ) by and among M EDIVATION , I NC . , a Delaware corporation having its principal place of business at 201 Spear Street, 3 rd Floor, San Francisco, California 94105, United States, its wholly owned subsidiary Medivation Prostate Therapeutics, Inc., a Delaware corporation having its principal place of business at the same location (such entities, collec … intellectual property right, in each case ((a) and (b)) with the legal right to grant to the applicable Person access, a right to use, or a license, or a sublicense (as applicable) to such material, Information, or intellectual property right without violating the terms of any agreement or other arrangement with any Third Party. 1.40 “Co-Promote Product” has the meaning set forth in Section 6.9(c). 1.41 “Co-Promotion” means those Detailing and promoti … proval occurs with respect to the country individually or as part of a regional application. 1.68 “FTE” means the equivalent of a full-time individual’s work time for a twelve (12) month period. In the event that any individual who works full-time during a given fiscal year works partially on Products or in furtherance of the Collaboration and partially on other work outside the Collaboration in the fiscal year, then the full-time equivalent to be attribut … criteria: [*]. 1.76 “IND” means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent Regulatory Authority in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 1.77 “Indemnified Party” has the mea … uct manufactured at the Standard Unit Cost. 1.104 “Marketing Authorization Application” or “MAA” means an application for Regulatory Approval in a country, territory or possession other than the Shared Territory. 1.105 “Marks” has the meaning set forth in Section 10.9. 12 [*] = Certain confidential inform
BayPine Acquires Relation Insurance Services | MergerLinks posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
Absolutely delighted to be joining Relation, a company I’ve admired and watched grow significantly over the past few years as they have honed their unique lab and machine learning approach to disease… | David Powell | 179 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update
Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d) Annual report pursuant to Section 13 and 15(d) Cover Cover Financial Statements CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS (Parenthetical) CONSOLIDATED STATEMENTS OF OPERATIONS CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Notes to Financial Statements BUSINESS SIGNIFICANT ACCOUNTING POLIC
Relation Insurance Acquires Crop Rx Insurance Services Skip to content Insurance Employee Benefits Health & Wellness Programs Compliance & HR Support Custom Benefits Consulting Retirement Benefits Executive Benefits Pharmacy Benefits Voluntary Benefits Business Insurance Workers Compensation General Liability Commercial Property Commercial Auto Loss Control Claims Management & Advocacy Cyber Liability Surety & Bonds Executive Liability Professional Liability Captives & Alternative Risk Business Owners Policy Small Business Insurance General Liability Commercial Propert … binars Type Press Release News Article Blog Post Date Newest First Oldest First Apply Mergers & Acquisitions Relation Insurance Acquires Crop Rx Insurance Services CHICAGO, May 14, 2026 — Relation Insurance Services (“Relation”) announced today their acquisition of the assets of Crop Rx Insurance Services, LLC (“Crop Rx”). The transaction went into effect on March 31, 2026; terms of the transaction were not disclosed. “We’re excited to join Relation,” said Michael Klepper
August 7, 2017 - DEVELOPMENT AND LICENSE AGREEMENT - 8-K: Current report filing | Rezolute, Inc. (RZLT) August 7, 2017 > Form 8-K > Rezolute, Inc. Document Links Form: 8-K Current report filing August 7, 2017 Complete Filing PDF » Includes filing and all documents Documents 8-K » DEVELOPMENT AND LICENSE AGREEMENT » PRESS RELEASE DATED AUGUST 7, 2017 » DEVELOPMENT AND LICENSE AGREEMENT Published on August 7, 2017 EXHIBIT 10.1 DEVELOPMENT AND LICENSE AGREEMENT This Development and License Agreement (this “ Agreement ”), dated as of August 4, 2017 (the “ Effective Date ”), is … Kallikrein Inhibitor program (“ PKI Program ”); WHEREAS, ActiveSite desires to grant to AntriaBio a license to practice and use such patents and know how pursuant to the terms and conditions of this Agreement; WHEREAS, AntriaBio wishes to partner with ActiveSite on its PKI Program, and therefore desires to receive a license to such rights from ActiveSite pursuant to the terms and conditions of this Agreement; and WHEREAS, ActiveSite and AntriaBio are, on the Effective Date, … license, other than licenses granted pursuant to this Agreement) of a Party to grant to the other Party access to, ownership of, or a license or sublicense under, such Know How, patent, material or other intellectual property, in each case as provided under this Agreement and without violating the terms of any agreement or other arrangement with any Third Party. 2.10 “ Diligent Efforts ” means, with respect to the Development or Commercialization of a Licensed Product in the … Product, any submission to a Regulatory Authority of any appropriate regulatory application, including any investigational new drug application filed with the FDA for authorization for the investigation of a Licensed Product or foreign equivalent thereof; new drug application or biologic license application or foreign equivalent thereof; submission to a regulatory advisory board; marketing authorization application; and any supplement or amendment to any of the foregoing. 2.3 … man or animal disease, disorder or condition; and (b) The unrestricted right to grant sublicenses subordinate to the terms of this Agreement. AntriaBio shall notify ActiveSite of each such sublicense, provide a copy of such sublicense upon request (with no redactions with respect to any payment obligations that, when paid, would be within the sco
Appointed as director of ML/AI research at Relation Therapeutics | Lotfollahi Skip to main content Home About The Lab Research Publications News Talks Recent posts Many Needles in a Haystack accepted at ICML 2026 DirMoE at ICLR 2026 — a fully differentiable Mixture-of-Experts router Our lab is awarded 2.9M$ from Medical Research Council to tackle kidney cancer using generative AI + massive multimodal data Starting January 2026 I have joined the scientific advisory board of Novo Nordisk Appointed as director of ML/AI research at Relation Therapeutics Appointed as director of ML/AI research at R … L and drug discovery. Read the press release on: [Twitter] , [Linkedin] . Tags: Award Edit this page Newer Post Starting January 2026 I have joined the scientific advisory board of Novo Nordisk Older Post I have joined ELLIS Copyright © 2026 Mo Lotfollahi.
Careers | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Careers Join us We are committed to creating the most interdisciplinary team to discover and develop transformational medicines. At Relation, we are looking for bright, passionate individuals who care about our mission. The mission is not easy, but the journey will be incredibly rewarding. How we operate matters to us and as such, our core values are at the centre of everything we do: 01 We believe in empowerment. We embody the freedom, independence and responsib
EX-10.19 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Exhibit 10.19 EXCLUSIVE LICENSE AGREEMENT by and between AMGEN INC. and PINTA BIOSCIENCES, INC. Dated as of September 7, 2012 ARTICLE 1 DEFINITIONS 1 ARTICLE 2 LICENSE GRANT; CLOSING 9 Section 2.1 Grant 9 &n … Agreement 22 Section 6.3 License Grant and Right of Reference 22 Section 6.4 Product Data; Regulatory 22 Section 6.5 Amendment of Japan Agreement 23 ARTICLE 7 REPRESENTATIONS AND COVENANTS 23 Section 7.1 Mutual Warranties 23 &nbs … same throughout the Territory (defined below); and W HEREAS , Amgen desires to grant such a license to Company in accordance with the terms and conditions of this Agreement. N OW , T HEREFORE , in consideration of the premises and the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: ARTICLE 1 DEFINITIONS All references to … ;3.9 (Records and Audits). “ BLA ” means (a) a Biologics License Application, supplemental Biologics License Application, or similar application filed or to be filed with the FDA, as described in Title 21 of the U.S. Code of Federal Regulations, Part 601, et seq. , or (b) any corresponding foreign application in another country or regulatory jurisdiction in the Territory, including, in the case of the European Union, a Marketing Approval Application filed … whether by ownership or license) by a Party or its Affiliates of the ability to grant to the other Party a license or access as provided herein to such Know-How, material, Patent Right, or other intellectual property right, without violating the terms of any agreement or other arrangement with any Third Party, or being obligated to pay any royalt
Supply chain resilience in relation to natural disasters: framework development - Monash University Skip to main navigation Skip to search Skip to main content Monash University Home Search content at Monash University Home Profiles Research units Research Infrastructure Projects Outputs Prizes Activities Press/Media Supply chain resilience in relation to natural disasters: framework development Adela Drozdibob , Amrik Sohal , Christopher Nyland , Sajad Fayezi Department of Management Research output : Contribution to journal › Article › Research › peer-review 24 Link opens in a new tab … similar technologies. For all open access content, the relevant licensing terms apply We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies Monash University data protection policy Link opens in a new tab About web accessibility Link opens in a new tab Report vulnerability Link opens in a new tab Contact us
Careers | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Careers Join us We are committed to creating the most interdisciplinary team to discover and develop transformational medicines. At Relation, we are looking for bright, passionate individuals who care about our mission. The mission is not easy, but the journey will be incredibly rewarding. How we operate matters to us and as such, our core values are at the centre of everything we do: 01 We believe in empowerment. We embody the freedom, independence and responsib
Discovery Collaboration Agreement Exhibit 10.35 Execution Version [*] indicates that a confidential portion of the text of this agreement has been omitted. DISCOVERY COLLABORATION AGREEMENT This Discovery Collaboration Agreement (this “ Agreement ”) is effective as of September 9, 2009 (the “ Effective Date ”) and is made by and between Arana Therapeutics Limited (ACN 002 951 877), an Australian company having offices at Level 2, 37 Epping Road, Macquarie Park, New South Wales 2113, Australia (“ Arana ”), and XOMA Development Corporation, a Delaware corporati … c) hereof. 1.10 [*] 1.11 [*] 1.12 “ BLA ” means a Biologics Licensing Application or New Drug Application (each as defined in the FDC Act) and any other equivalent marketing authorization application or other license, registration or application seeking approval from a Regulatory Authority to market a Licensed Product in the Field in the Territory. -2- 1.13 [*] 1.14 [*] 1.15 [*] 1.16 “ Change of Control ” means any transaction or series of transacti … ed by an employee of the Receiving Party and/or its Affiliates without the aid, application or use of confidential information disclosed by the Disclosing Party (and such independent development can be demonstrated by the Receiving Party’s written records), provided such independent development does not breach any of the Receiving Party’s obligations under this Agreement. 1.22 “ Control ” or “ Controlled ” means, with respect to any (a) mate … nted pursuant to this Agreement) by a Party or its Affiliates of the ability to grant to the other Party access, ownership, a license and/or a sublicense as provided herein under such item or right without violating the terms of any agreement or other arrangement with any Third Party as of the time such Party would first be required hereunder to grant the other Party such access, ownership, license or sublicense. -3- 1.23 “ Disclosing Party ” has the meaning … eissue, disclaimer or otherwise, or (b) a claim of a pending parent patent application that was filed and is being prosecuted in good faith and has not been abandoned or finally rejected without the possibility of appeal or refiling. -8- 1.70 [*] 1.71 “[*] Materials ” has the meaning specified in Section 5(e) hereof. 1.
Distribution of Solutes within the Developing Grape Berry in Relation to Its Morphology | American Journal of Enology and Viticulture Skip to main content Advertisement Main menu Home Information For Authors Reviewers Open Access Publishing AJEV Preprint and AI Software Policy Submission Subscribers Proprietary Rights Notice for AJEV Online Permissions and Reproductions Content Current Volume AJEV and Catalyst Archive Best Papers ASEV National Conference Technical Abstracts Back Orders About Us Feedback Alerts Help Login ASEV MEMBER LOGIN User menu Log in Search Search for this keyword Advance
The One Where We Build a Pharma from Scratch Subscribe Sign in The One Where We Build a Pharma from Scratch FOUNDING BIO #004 +1 Jonty Corrin , Ines Ullmo , Nelli Morgulchik , and 2 others Oct 22, 2025 11 2 3 Share future.bio is built on trust, transparency, and minimal bullsh*t. That’s exactly the spirit behind this interview series - casual and candid conversations with some of the most exceptional builders working at the intersection of computation x biology. This week, we’re in conversation with Jake Taylor-King , Co-Founder of Relation Therapeutics (DCVC, NVIDIA, Magnetic) - an end-to-end … work on pure mathematical problems, though I was beginning to look for ways to apply them more practically during my PhD. When I finished my master’s, I had an offer from Cambridge to move into a more economics-focused PhD, and I thought that might be my route into the “real world.” But then I came across this new interdisciplinary bioscience program that offered funding for maths PhDs, so I took it, thinking I could just sit through the biology courses and still graduate as … y synergistic antiviral drug combinations. Receiving our first Gates Foundation grant was probably the first major milestone. Another was David joining us as CEO - he’s truly strategic and great to work with has shaped our direction. Bringing in key investors like DCVC, Magnetic, and most recently NVIDIA, helped accelerate our growth. Finally, our deals with GSK have also been transformative for us, demonstrating that our vision is delivering on its promise. What was the bigg
Distribution and density of moose in relation to landscape characteristics: Effects of scale USGS Publications Warehouse Skip to main content An official website of the United States government Here’s how you know Here’s how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. Menu USGS Publications Warehouse Explore Explore recent publicati … atial model of density of moose developed in this study represents an important application for effective monitoring and management of moose in the boreal forest. ?? 2005 NRC. Suggested Citation Maier, J., Ver Hoef, J., McGuire, A., Bowyer, R., Saperstein, L., and Maier, H., 2005, Distribution and density of moose in relation to landscape characteristics: Effects of scale, in Canadian Journal of Forest Research, v. 35, no. 9, p. 2233-2243, https://doi.org/10.1139/x05-123. Pub
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 EXECUTION VERSION Exhibit 10.1   Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential.   Collaboration and License Agreement   between   Ionis Pharmaceuticals, Inc.   and   Novartis Pharma AG   COLLABORATION AND LICENSE AGREEMENT   This COLLABORATION AND LICENSE AGREEMENT (the “ Agreement ”) is entered into as of August 2, 2023 (the “ Execution Date ”) by and between Ionis Pha … d   WHEREAS , Novartis desires to receive from Ionis, and Ionis desires to grant to Novartis, an exclusive worldwide license under this Agreement to research, develop, manufacture, and commercialize the Licensed Products under the terms and conditions set forth herein.   NOW, THEREFORE , in consideration of the respective covenants, representations, warranties, and agreements set forth herein, the Parties hereto agree as follows:   ARTICLE 1 OVERVIEW   The … to any Research Report required pursuant to Section 2.10.2 (Research Reports), submit a Development Candidate Data Package to the JRC for review and discussion in order to determine whether to recommend to the JSC that such Licensed Compound be designated by the JSC as a Development Candidate. If a Party reasonably believes that a Licensed Compound identified or evaluated by the other Party satisfies the Development Candidate Criteria but the evaluating Party did not provide … search Term, the Party that identified or evaluated such Licensed Compound will submit a Development Candidate Data Package with the information and data that is already in such identifying or evaluating Party’s possession to the JRC for review and discussion in order to determine whether to recommend to the JSC that such Licensed Compound be designated by the JSC as a Development Candidate. Any Licensed Compound recommended to the JSC by the JRC in accordance with this … ew and discuss such Development Candidate Data Package and determine whether to submit such Development Candidate Data Package to the JSC for the JSC to determine whether to designate the applicable Proposed Development Candidate as a Development Candidate.   (b)       After the JSC’s receipt of (i) a Deve
%PDF-1.7 %���� 1 0 obj >/Metadata 489 0 R/ViewerPreferences 490 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[o$G����|ZH�:㖗3�� {܋ٹ�=�z��T*�u��Ҩ��{~�7�JRK�8g0VW`0$�d�zsw}�\��ë7���Շ�E��ջ����z��v��o˫����z�y����=��q��X߽~]|���~�UY���,E��(*!���������w���^��gS\��} �T�^%[�[��� ��E���E�O^������W��J.�4��\�P�ZU��d�Ɠo����(�w�_% ��R��j!e��#\�B� Bş��������S�������������}H�ï��� 3�z�����cF���8-3͢��� y?V�/زZ b��� 3���ݲ�7~����y�q�ʅz� k͢y
Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d) Annual report pursuant to Section 13 and 15(d) Cover Document and Entity Information Financial Statements Consolidated Balance Sheets Consolidated Balance Sheets (Parenthetical) Consolidated Statements of Operations Consolidated Statements of Changes in Stockholders' Equity Consolidated Statements of Cash Flows Notes to Financial Statements Organization and Description of Business Summary of Significant Accounting Policies Collaboration and Stock Purchase Agreements and Asset Acquisitions Inventory Property and Equipment Fai … m for the treatment of Menkes disease, through the filing of Cyprium’s New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”). Cyprium also remains eligible to receive up to an additional $12.0 million in development milestones, payable as follows: (i) $3.0 million upon acceptance by the FDA of the NDA for review; and (ii) $9.0 million upon FDA approval of the NDA and transfer of CUTX-101 to Sentynl. Cyprium would also be eligible to receive up to $25
Clause 29 Annual Disclosure of Contracted Services, Donations, Grants and Sponsorship (including in relation to events/meetings) Provided to Patient Organisations Skip to main content Code 2024 ABPI Code of Practice launched, with a new constitution and procedure for the PMCPA 2024 Interactive ABPI Code of Practice Documents outlining the changes to the ABPI Code Previous Codes of Practice Guidance and Q&As Guidance Q&As by Topic OR Clause 2024 Code Clause 12 Q&As 2024 Code Clause 10.4 Q&As PMCPA social media guidance Cases Ongoing cases Completed cases Advertised Sanctions Com … icly disclosed in 2025, and for each calendar year thereafter, companies should submit a link via the relevant Disclosure UK gateway. The link should take visitors from Disclosure UK to patient organisation disclosure information published on the company’s website. Clause 29.1 Further Information An indication of the patient organisation’s total income and/or the company’s support as a percentage of the patient organisation’s total income may be given. Companies are encourage … organisation must include: • the monetary value of each financial contribution (grant or sponsorship) to include a description that is sufficiently complete to enable the reader to understand the nature of that support or the arrangements in accordance with Clauses 23 and 10 • the monetary value for each non-financial and/or indirect support (donation); the published information must also include a clear description of each donation that is sufficiently complete to enable the
DCVC | Relation Therapeutics partners with GSK in history-making… Skip to content DCVC Close Menu Companies About DCVC Bio Team News & Insights Careers Media Resources Feature Read our 2024 Climate Impact Report FEATURE: Read our 2024 Climate Impact Report Dismiss DCVC Companies About DCVC Bio Team News & Insights Careers Search DCVC Search Search Open Menu News & Insights News Relation Therapeutics partners with GSK in history-making collaboration to create new treatments for fibrosis and osteoarthritis By Jason Pontin Blockbuster deal validates Relation’s “ lab-in-the-loo
Lindsay Edwards on building AI... - Transcribed - Apple 播客 搜索 主页 新发现 排行榜 搜索 5月8日 42 分钟 Lindsay Edwards on building AI that actually works in biology Transcribed 播放 Lindsay Edwards went from producing UK top ten singles with Sting and Whitney Houston to pioneering the first data science group at GSK — and he's carried the same creative instinct into machine learning ever since. Now CTO of Relation Therapeutics, he's one of the clearest-eyed voices in the industry on where AI in biology is genuinely working and where it's still mostly noise. Lindsay joined Benchling CEO Sajith Wickramasekara to
CSO Placement at Relation Therapeutics About Insights Expertise Life Science Executive Search Deep Tech Executive Search Defense Tech Executive Search Biotech Executive Search Venture Capital Executive Search Our Work Case Studies Placements Contact Discuss An Executive Search Get Started Get Started Occam Places Edith Hessel as CSO and Lindsay Edwards as CTO at Relation Therapeutics Relation Therapeutics, a London-based breakthrough AI-enabled drug discovery platform company leveraging active-graph machine learning (ML) in combination with single-cell and deep clinical analysis to query biolo
Lindsay Edwards | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Team Lindsay Edwards Chief Technology Officer Lindsay Edwards is Relation's CTO and President of Platform. Originally a specialist in systems biology, he joined GlaxoSmithKline in 2014 from the Physiology faculty at King's College London. At GSK, he founded the company's first Data Science group, ultimately becoming VP of AI/ML for UK & Europe and VP of AI/ML Engineering. He subsequently built and led an AI/ML team at AstraZeneca, contributing to
Slush Slush 2026 Attendees Speakers Startups Spinouts Investors LPs Partners Media Volunteers Slush week Side Events Slush 100 Livestream Afterparty Meetings Guide to Helsinki About Us About Us Newsroom FAQ Slushtainability Slush365 Slush Platform Buy tickets Speakers 2025 > Jake Taylor-King Jake Taylor-King Co-founder & CIO at Relation Prior to co-founding Relation Therapeutics, Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research pri … clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access. Stay Connected Sign up for our newsletter Who a
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Jake Taylor-King | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Team Jake Taylor-King Chief Innovation Officer Prior to co-founding Relation Therapeutics, Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from the University of Bristol (BSc), the University of Oxford (MSc, D.Phil), and the University of Cambridge (MPhil
Relation Therapeutics - Scientific Team | The Org Platform Enrich Pricing Log in Sign up Relation Therapeutics Teams Scientific Team Unverified Scientific Team 5 people · 0 jobs The Scientific Team at Relation Therapeutics is dedicated to advancing drug discovery and development through cutting-edge research. Comprised of experts in sequencing, functional genomics, and target validation, they work collaboratively to identify and validate new therapeutic targets, ensuring the progression of innovative treatments from concept to clinic. People ( 5 ) AV Amaia Vilas Senior Director, Molecular Pr
Proximity determines donor candidacy during DNA double-stranded break homology directed repair | bioRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Proximity determines donor candidacy during DNA double-stranded break homology directed repair View ORCID Profile Charles D Yeh , View ORCID Profile Lilly van de Venn , Susanne Kreutzer , Xinhe Zheng , Naomi C. Cantos , Markus Schröder , Robin Hofmann , Felix E. Gerbaldo , Alexandra Clemens , View ORCID Profile Beeke Wienert , View ORCID Profile Christopher D. Richardson , Zacharias Konta
Jacob Corn - Scientific Advisor at Relation Therapeutics | The Org Platform Enrich Pricing Log in Sign up Relation Therapeutics Jacob Corn Unverified Jacob Corn Scientific Advisor Contact Jacob Corn is the Professor of Genome Biology at ETH Zürich. His research aims to bring about the end of genetic disease through the development and application of next-generation genome editing technologies. Jacob is committed to the improvement of human health through the fundamental understanding of disease mechanisms. Over the last fifteen years he has bridged academia and industry, working in therapeut
Novartis news, this got comparatively overlooked in the press around that but wanted to highlight the additional $26M investment Relation also announced this week from insiders NVIDIA’s nVentures , and DCVC and Magnetic Ventures. Honoured for them to each materially increase support alongside our pharma strategics. NVIDIA are, and ever more so continue to be, the most incredible AI technology partners, so much more than investment, or compute - but thought-partnership: and a focus on building the ecosystem to ship therapies faster than ever. https://lnkd.in/enHRg-f3 Christine Aylward Vega Shah
Benjamin Swerner - London Tech Week 2027 {isScrolled = window.scrollY > 0;});"> HOME ATTEND WHY ATTEND FREQUENTLY ASKED QUESTIONS INCLUSIVITY & ACCESSIBILITY INTERNATIONAL EVENTS WHAT'S ON EXPERIENCE TECH SHOWCASE FRINGE EVENTS CALENDAR AGENDA SPEAKERS CONTENT AGENDA SPEAKERS STAGES THEMES ADVISORY BOARD PARTNER WHY PARTNER 2026 PARTNERS 2026 EXHIBITORS PARTNER SUCCESS STORIES MEDIA MEDIA & STRATEGIC PARTNERS PRESS COVERAGE PITCH BOOTH TECH NEWS & INSIGHTS NEWSLETTER REGISTER YOUR INTEREST EXHIBIT & SPONSOR Speakers Loading Benjamin Swerner Co-Founder & COO, Relation Benjamin is the Co-Founder
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Benjamin Swerner | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Team Benjamin Swerner Chief Operating Officer Benjamin Swerner is a co-founder and the Chief Operating Officer of Relation. At Relation, he is focused on the operational, corporate development and strategy components of the business. Previously, Benjamin worked at DN Capital, one of Europe’s oldest venture firms, where he focused on investing in healthcare and deep-tech. Benjamin studied Natural Sciences at Cambridge and subsequently Cognitive Neuros
Relation of body fat distribution to metabolic complications of obesity Relation of body fat distribution to metabolic complications of obesity J Clin Endocrinol Metab . 1982 Feb;54(2):254-60. doi: 10.1210/jcem-54-2-254. Authors A H Kissebah , N Vydelingum , R Murray , D J Evans , A J Hartz , R K Kalkhoff , P W Adams PMID: 7033275 DOI: 10.1210/jcem-54-2-254 Abstract The importance of body fat distribution as a predictor of metabolic aberrations was evaluated in 9 nonobese and 25 obese, apparently healthy women. Plasma glucose and insulin levels during oral g
%PDF-1.6 %���� 62257 0 obj > endobj 62277 0 obj >/Filter/FlateDecode/ID[ ]/Index[62257 30]/Info 62256 0 R/Length 95/Prev 15700748/Root 62258 0 R/Size 62287/Type/XRef/W[1 2 1]>>stream h�bbd``b�}$����`5̗`S,�U bՀu�� �ʋ���3��`� %�ˁ� �����������H����'@��D endstream endobj startxref 0 %%EOF 62286 0 obj >stream h��Y}pT�?����&/��{���s7 ��&&�Dxn��D>���$F�����$,�H���Ҥ (��`A�vq�Dk���t �v�E�� ��Zl{�}ow�n1jg��;��s�w~�����e�����) 0B�cĘ 8��o[��8��e�>;pV`��P�����]�"ɰ B?��@4ˉ�3�h\M��.h��^��46�61V�� FDB���3S� ٠����ޢ��� ������z3�e�S& �� �{�fk� ���H�F���,��pD��\r�I … Ku�2��k��¹�6;�.r~���*�O��a�`� �{� ��%���`i��dy�}�ӏo#! amy�*�Jly��[� >stream application/pdf CMYK_GSK_Logo_Full_Colour_CMYK 2021-12-09T21:31:56Z 2021-12-09T21:31:56Z 2021-12-09T21:31:55Z Adobe Illustrator 26.0 (Macintosh) uuid:6774d1fe-9a9e-be4c-b023-c0d5d0e48380 xmp.did:bf9f2caf-e2be-47ba-8644-34b5e13c13fa uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:8bafa233-b96d-47c8-a144-d6d1fce5c7cc xmp.did:02720d29-0b8d-45a6-84bb-989449acd525 uuid:5D20892493BFDB11914A8590D … ���K���Mn�g�B�e���� CC�x��ilj����Ф��_�'���Z� endstream endobj 3 0 obj >stream application/pdf CMYK_GSK_Living_Gradient_CMYK 2021-12-09T21:06:30Z 2021-12-09T21:06:30Z 2021-12-09T21:06:29Z Adobe Illustrator 26.0 (Macintosh) uuid:600c83c3-a602-3443-9867-2b3014ace87f xmp.did:bf9f2caf-e2be-47ba-8644-34b5e13c13fa uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:8bafa233-b96d-47c8-a144-d6d1fce5c7cc xmp.did:02720d29-0b8d-45a6-84bb-989449acd525 uuid:5D20892493BFDB11914A8590D3 … �l�,*;\�,��%_� ˊ �!$ittB�ɠ�����x�� 0_xخ endstream endobj 8 0 obj >stream application/pdf CMYK_GSK_Living_Gradient_CMYK 2021-12-09T21:06:30Z 2021-12-09T21:06:30Z 2021-12-09T21:06:29Z Adobe Illustrator 26.0 (Macintosh) uuid:600c83c3-a602-3443-9867-2b3014ace87f xmp.did:bf9f2caf-e2be-47ba-8644-34b5e13c13fa uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:8bafa233-b96d-47c8-a144-d6d1fce5c7cc xmp.did:02720d29-0b8d-45a6-84bb-989449acd525 uuid:5D20892493BFDB11914A8590D3 … 4Z-#n^��8�Z��Z� $���՚\-% ơ%�K��b�`�_�� endstream endobj 19 0 obj >stream application/pdf KPl.pie 2023-02-21T19:04:41Z 2023-02-21T19:04:41Z 2023-02-21T19:04:39+01:00 Adobe Illustrator 27.2 (Windows) uuid:ce10ba46-8902-4a31-930e-0f3b8a4f41b3 xmp.did:ff7ed5c6-d0df-b147-b7bc-fc9f02b0c59e uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:7fa
Wildlife Buddy Resident Sponsorship - Northwoods Wildlife Center Skip to content Wildlife Emergency Wildlife Emergency $ 0.00 About Us Menu Toggle Contact Us Mission and History Common Questions Board and Staff Members Volunteering Subscribe to our Newsletter Internships Business Sponsors Financials Wildlife Rescue Menu Toggle Wildlife Emergency Get the Lead Out Education Menu Toggle Daily Tours – Starting in May Wildlife Education Programs Wildlife Ambassadors Support Us Menu Toggle Wildlife Baby Shower Business Sponsor Info Sponsor Ambassador Animals Membership Menu Toggle My Membe
%PDF-1.7 %���� 1 0 obj >/Metadata 876 0 R/ViewerPreferences 877 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 14 0 R 15 0 R 16 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=ksܸ��]��0�OÔE �G�J����^�۽����$ F�X�� a�]Y��DVr.5/���3��kq&��B,o ��+Κ��h�lϤjg��#������>Ǣ_n~-�:��ըI��8/�&+S`"\�*f�!�]�����h�� ��t����8S߬+��p��%�x�!;V���Ɍ�4%�� �a�L��U �A"�7r!�^-�ڲ��ӭ8|2x�8ŏ����_|{Xl���7�=����.���V���r�?��M�D���x�+v�D�Õ���x[�j��[M���@� V/��[E ����j�h�X��� �c������-� … t;knowledge</database>
 </properties>
</im> application/pdf endstream endobj 879 0 obj >/Font >>>/Fields[]>> endobj 880 0 obj > endobj 881 0 obj > endobj 882 0 obj > endobj 883 0 obj > endobj xref 0 2 0000000000 65535 f 0000272243 00000 n 869 1 0000272421 00000 n 876 1 0000272960 00000 n 879 5 0000276812 00000 n 0000276941 00000 n 0000276985 00000 n 0000277077 00000 n 0000277155 00000 n trailer ]/Prev 272058>> startxref 278348 %%EOF 891 0 o … t;knowledge</database>
 </properties>
</im> application/pdf Terms and Conditions for the Provision of Registered Office Services by MCS (Exempted Limited Partnership) endstream endobj 884 0 obj >69]/P 55 0 R/Pg 3 0 R/S/Annot>> endobj 885 0 obj >stream H��WMs�8��W�|2�F�ؙ�����z��db��!�-�6�$J�'�� �@�AP �3����F��ׯg�v���\ ��~��; ��s� ���m�����px�V��U��v�l���T>�My�7M���W��(���� +X��&��[�L���/�Q����(�Q��`�8� Y�'��u�߈� ��٨�n��I���rEfw�78
%PDF-1.7 %���� 5930 0 obj > endobj xref 5930 54 0000000016 00000 n 0000007248 00000 n 0000007398 00000 n 0000007436 00000 n 0000008423 00000 n 0000009231 00000 n 0000009694 00000 n 0000009723 00000 n 0000009840 00000 n 0000010538 00000 n 0000010793 00000 n 0000010908 00000 n 0000010947 00000 n 0000011087 00000 n 0000012046 00000 n 0000012754 00000 n 0000013459 00000 n 0000014092 00000 n 0000014780 00000 n 0000015589 00000 n 0000016397 00000 n 0000017117 00000 n 0000032051 00000 n 0000034701 00000 n 0000034777 00000 n 0000034876 00000 n 0000035027 00000 n 0000035141 00000 n 0000035212 00000 n 0 … 15+02:00 1 False False 211.666667 150.283333 Millimeters Default Swatch Group 0 application/postscript nn_logo_rgb_white.eps endstream endobj 5963 0 obj > endobj 5964 0 obj > endobj 5965 0 obj > endobj 5966 0 obj >/Shading >>>/Subtype/Form>>stream H�*�2PH��wR�\�&�zFf�Ff ��&zf���F�(l$%���zfF��&� �&z���憖 ɹ\N �� � � �\R�� endstream endobj 5967 0 obj > endobj 5968 0 obj > endobj 5969 0 obj > endobj 5970 0 obj >/ExtGState >>>/Subtype/Form>>stream H��w6PH.V0�313��F … ��b`&1��������G����hvG�n u� 4��ݡ�1���r�D�፴�����b > endobj 60 0 obj >stream application/postscript Print (Aya Massoulier ) 2024-09-12T13:14:04+02:00 2024-09-12T13:14:04+02:00 2024-09-12T13:14:04+02:00 Adobe Illustrator 28.6 (Macintosh) xmp.iid:2a3fa3ae-3741-49bb-abc0-2b5c32be9ceb xmp.did:2a3fa3ae-3741-49bb-abc0-2b5c32be9ceb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:53e4eca0-3c37-4bc4-ae1c-0086d7d997a7 xmp.did:53e4eca0-3c37-4bc4-ae1c-0086d7d997a7 uuid:5D20892 … 5 2020-04-29T13:27:27+02:00 Adobe Illustrator 24.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:53e4eca0-3c37-4bc4-ae1c-0086d7d997a7 2024-09-12T13:13:46+02:00 Adobe Illustrator 28.6 (Macintosh) / saved xmp.iid:2a3fa3ae-3741-49bb-abc0-2b5c32be9ceb 2024-09-12T13:14:04+02:00 Adobe Illustrator 28.6 (Macintosh) / Print Adobe PDF library 15.00 1 False False 600.000000 426.000000 Pixels Cyan Magenta Yellow Black Default Swatc … �*ũ����B>z� ^��J���=��b�|�,�L�'~d�q� endstream endobj 126 0 obj >stream application/postscript Print 2020-04-29T13:27:27+02:00 2020-04-29T13:27:27+02:00 2020-04-29T13:27:27+02:00 Adobe Illustrator 24.1 (Macintosh) xmp.iid:13b706f3-3561-4cc8-bb15-9afb03b64705 xmp.did:13b706f3-3561-4cc8-bb15-9afb03b64705 uuid:5D20892493BFDB11914A8590D31508C
Relation's CEO David Roblin on Times Radio's "CEO of the Week" | Relation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … rter and Senior Reporter - Dr Alison Vincent, CBE FREng, Chair of the MacRobert Award Committee - Pankaj Chandak, Paediatric transplant Fellow at Great Ormond Street and Evelina Children's Hospital …more 45 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Hamad Al-Zeera MBA, Associate PRM, CIPA, Series 7 8mo Report this post #AI #LLM -s #ChatBot -s enter the science lab AI tech firms are creating specialized apps tailoring the chatbots t … omment Share Copy LinkedIn Facebook X To view or add a comment, sign in Mustafa Prize 1,615 followers 8mo Report this post 🧭 At the 10th STEP (Science and Technology Experience Exchange), researchers discussed the transformative role of artificial intelligence in the future of science and life. What once existed only in the realm of data and algorithms has now become a powerful tool for saving lives, protecting the planet, and gaining deeper insights into living systems. ⚕️F … reatment, from discovery to life. ⏭️The 10th STEP was a part of the 6th Mustafa Prize. . . . ___________________________________________________________ #ArtificialIntelligence #MustafaPrize #STEP #Biotechnology #PrecisionMedicine #ScienceServingLife 🌍 #AI …more 12 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 15,929 followers View Profile Connect Explore related topics How AI is Transforming Clinical Trials How AI Improves Patient Outcomes in
10-Year Partnership: Adapting to the Market Together | Keepit Keepit Live World Tour: Join us in a city near you Login Keepit Platform Login Partner Portal Login Support EN DE EN ES FR PT Solutions Why Keepit Keepit ROI Calculator Trust center Keepit platform Platform security Data center security Responsible AI Use cases Ransomware recovery Compliance Read customer case Read the report Services Services overview Microsoft 365 Microsoft Entra ID Microsoft Power Platform Microsoft Dynamics 365 Microsoft Azure DevOps Salesforce Google Workspace Zendesk Confluence Jira Jira Service Management Okt
%PDF-1.4 %���� 1 0 obj > endobj 5 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … q�h:b��:�O �7"[)?����z?�Խ~C�iC��n.��a��S��;c��![����'���^*4)r��1�v��+RFP��F�#��N�$�K`��O*V{�JGJ�S�:���*Q:�9�耫T�X�3�H����^�A-�D��v��Y���~��2i���}7�Gf(nJ}��~��~��z�#��k�a*� x���K4��d ^�+R�w����*;0ٛϐ@?7��������S�42T�� QPY%�8��R� ��R����Sl??�e�I�&�+�s�����q����t�2�t�����D �*�����ɐ�v��̋�%�K��-�=(!-�k�>���ӷ�9���i�S|W��.OK~1כ�A�HJ�A���Û�go͙y%�ր�֠�@]����|���A����i�}\WѨ���68��Q�{�Y=���/T�����ဗ,0&�q!6Q��`�W��� ɮk���1�|�Ag�� �,*�o���k … ���o8��$�'}���8�UPv�h�3�g� ������y �V� +$�>X[o6�$ֆ>;l/Ѵ�zKo��ʽ��_k|6�؎RFp z�I�+��ԓ�Fg�T���0, 9B��INd��S����3� ��Q�O�q���IR�t�M���B��JJI����9V�u}��0Ao��&�)�`O�-Z���. ,1 VP i���x�I�l���$�`�����J��K$��'*Y�}�>v0Y�R�5Z�Q�!c���j:l �� �� ~y��1�M8/��3܅L����sinE%S��'��҉� o�v�*=2��vIs���%��Q���%7�_ $����U� ���gK��%\� � �J �ԩ_�%r�����K-D*�J�H��sg��:�8֞����O� :�!lf�����c��x� �R\K%/g�9ƺ��� �TűTՎ�}�����ij�PK � u#"Z�a!������+����5Y�^b��,+��Y�e�jVX43� … ���;�_$+�&�����b��˴���*=�T���ؖq�K#�ܩv�h�?�t�C-L��|� ���hD��ύ�q���� � ����RFP��}�[�k�K.��� ��^=a�b���Bh�����b�"7d�kB.d�K�p4�g�@f M�A��,�(Ab��� fY�����cH�o��R�(fV��?����VIn�g@��b�: �,�$��m7�'�N+�?�Kȥ��y�)+*r��g=t��wy@�PL������B�T�� h7A�ص� ����Q�\�� � c�s �o4�S�0 ��O��O~�1W;TT@��(!��'!K˦�5b!�Gx�� @���8e$�C�fa�*�����V͊iQC�A�t�� � bj ]�v�v `�0�^�|XK�h��2�{~��E@!� L�`͢I _�����.-�����9Ji�F/��L��i��+1��� H�II���� *mV�%Z���R� … o�D��'�? C�,%b �_a��9�[�h�z���&��}Ԯ�� I�?o�T����Lj�E]�:'�K� �#KEQ$ ��- RFP 1_o}ʑ�&��;؏� =x�e��H��}��mc!�����Z��3�P�YaC�F�9���w�*��=���8��*#�?���M�O6�Z�VN��Z �=����]!�PK�m��m ��i��9�Xb�w 9��M�B�o����ٕ$ւs?�Kv�2��@ � I�" �>������C+ _����Q/C%���8ܳH'-˵�jb `�� "�K�N�$���8�T�x�'�U����(# �0OJ����k��J�J��V�,ұ#,�"�!-H�B��
Our science | Relation Skip to content Relation Therapeutics Menu Primary Navigation Home Our science Our pipeline Our team Join us News Our Science Embedding the patient, from the earliest stages of innovation. We constantly ask which new technologies will allow us to drive the progression of our programmes. To do this, we create experimental and computational systems to understand the biological processes in human health and disease. Our technologies enable us to generate, analyse and interpret human data about the behaviour of genes, cells and tissues in an unparalleled fashion. Above all,
Hunt UK Visa Sponsors Filters Jobs Log In Hunt UK Visa Sponsors Find jobs from UK licensed visa sponsors — Companies House verified, updated daily. About How does it work Contact Us Find Work Jobs Jobs by Role Register of Licensed Sponsors Visa Types Sponsor Statistics International Student Resources Blog Glossary Occupation Eligibility Income Tax Calculator ILR Tracker Developer API & MCP Sponsorship by Nationality Content on this site is for general information only and does not constitute legal advice. Always consult a regulated UK immigration solicitor for advice specific to your situa … genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines. Suggest an edit Claim this company Jobs (~3 days delayed) in United Kingdom Get job alert from this company You're seeing delayed jobs. Sign up free to unlock fresh jobs. Senior Scientist, Biologics Drug Discovery Relation Therapeutics Limited About Relation Relation is a sector defining TechBio company developing trans … ited issued recently? Where is Relation Therapeutics Limited located? How can I apply for a sponsored job at Relation Therapeutics Limited ? Is Hunt UK Visa Sponsors affiliated with Relation Therapeutics Limited ? Can Hunt UK Visa Sponsors help me get a job or sponsor my visa? How accurate is the information about Relation Therapeutics Limited ?